Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity

Smith, 1999, Stop TB: is DOTS the answer?, Indian J Tuberc, 46, 81 Arora, 2002, DOTS strategy in India – the challenges, Curr Med J North Zone, 8, 19 Higuchi, 2007, NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis, World J Gastroenterol, 13, 6003, 10.3748/wjg.13.6003 Teixeira, 2011, Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients, Mem Inst Oswaldo Cruz, 106, 716, 10.1590/S0074-02762011000600011 Mitchell, 1975, Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites, Clin Pharmacol Ther, 18, 70, 10.1002/cpt197518170 Nelson, 1976, Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat, Science, 193, 901, 10.1126/science.7838 Timbrell, 1982, Studies on hydrazine hepatotoxicity. 2. Biochemical findings, J Toxicol Environ Health, 10, 955, 10.1080/15287398209530309 Lee, 2003, Drug-induced hepatotoxicity, N Engl J Med, 349, 474, 10.1056/NEJMra021844 Santos, 2013, N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients, Int J Tuberc Lung Dis, 17, 499, 10.5588/ijtld.12.0645 Chen, 2006, The influence of various genotypes on the metabolic activity of NAT2 in Chinese population, Eur J Clin Pharmacol, 62, 355, 10.1007/s00228-006-0110-6 Kinzig-Schippers, 2005, Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?, Antimicrob Agents Chemother, 49, 1733, 10.1128/AAC.49.5.1733-1738.2005 Singh, 1995, Antituberculosis treatment-induced hepatotoxicity: role of predictive factors, Postgrad Med J, 71, 359, 10.1136/pgmj.71.836.359 Lee, 2010, NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis, Int J Tuberc Lung Dis, 14, 622 Bose, 2011, Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis, J Gastroenterol Hepatol, 26, 312, 10.1111/j.1440-1746.2010.06355.x Roy, 2001, Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ‘null’ mutation, J Gastroenterol Hepatol, 16, 1033, 10.1046/j.1440-1746.2001.02585.x Vuilleumier, 2006, CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis, Eur J Clin Pharmacol, 62, 423, 10.1007/s00228-006-0111-5 Du, 2013, Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis, Mol Biol Rep, 40, 3591, 10.1007/s11033-012-2433-y Mitchel, 1973, Acetaminophen induced hepatic necrosis. IV. Protective role of glutathione, J Pharmacol Exp Ther, 187, 211 Hussey, 1991, Variation in the expression of mu-class glutathione S-transferase isoenzymes from human skeletal muscle, Biochem J, 273, 323, 10.1042/bj2730323 Huang, 2003, Cytochome P4502E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis, Hepatology, 37, 924, 10.1053/jhep.2003.50144 Huang, 2007, Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury, J Hepatol, 47, 128, 10.1016/j.jhep.2007.02.009 Sun, 2013, GSTM1 and GSTT1 null polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis, Int J Tuberc Lung Dis, 17, 17, 10.5588/ijtld.12.0447 Leiro, 2008, Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population, Liver Int, 28, 835, 10.1111/j.1478-3231.2008.01700.x Ladero, 1996, RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma, Gut, 39, 330, 10.1136/gut.39.2.330 Benichou, 1990, Criteria of drug-induced liver disorders. Report of an international consensus meeting, J Hepatol, 11, 272, 10.1016/0168-8278(90)90124-A Prati, 2002, Updated definitions of healthy ranges for serum alanine aminotransferase levels, Ann Intern Med, 137, 1, 10.7326/0003-4819-137-1-200207020-00006 Roe, 1996 Fukino, 2008, Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients, J Toxicol Sci, 33, 187, 10.2131/jts.33.187 Sobti, 2006, Interaction of passive smoking with GST (GSTM1, GSTT1, and GSTP1) genotypes in the risk of cervical cancer in India, Cancer Genet Cytogenet, 166, 117, 10.1016/j.cancergencyto.2005.10.001 Purcell, 2007, PLINK: a toolset for whole-genome association and population-based linkage analysis, Am J Hum Genet, 81, 559, 10.1086/519795 Barrett, 2005, Haploview: analysis and visualization of LD and haplotype maps, Bioinformatics, 21, 263, 10.1093/bioinformatics/bth457 Pande, 1996, Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study, Thorax, 51, 132, 10.1136/thx.51.2.132 Kumar, 2010, Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome, Hepatology, 51, 1665, 10.1002/hep.23534 Cho, 2007, Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis, Tuberculosis (Edinb), 87, 551, 10.1016/j.tube.2007.05.012 Huang, 2002, Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis, Hepatology, 35, 883, 10.1053/jhep.2002.32102 Sodhi, 1996, Study of oxidative stress in isoniazid induced hepatic injury in young rats with and without protein energy malnutrition, J Biochem Toxicol, 11, 139, 10.1002/(SICI)1522-7146(1996)11:3<139::AID-JBT6>3.0.CO;2-L Chatterjee, 2010, GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs, J Clin Pharm Ther, 35, 65 Li, 2013, GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis, Eur J Clin Microbiol Infect Dis, 10.1007/s10096-013-1831-y Deka, 2010, Role of CYP2E1 gene polymorphisms association with hepatitis risk in Northeast India, World J Gastroenterol, 16, 4800, 10.3748/wjg.v16.i38.4800 Kim, 1995, Interindividual variability o f chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms, Clin Pharmacol Ther, 57, 645, 10.1016/0009-9236(95)90227-9 Singh, 2009, Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients, Mol Diagn Ther, 13, 49, 10.1007/BF03256314 Anitha, 2003, Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India, Int J Mol Med, 11, 125 Sabbagh, 2011, Arylamine N-acetyltransferase2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey, PLoS One, 6, e18507, 10.1371/journal.pone.0018507 World Health Organization, 2010 Acharya, 1996, Fulminant hepatitis in a tropical population: clinical course, cause and early predictors of outcome, Hepatology, 23, 1448, 10.1002/hep.510230622